<div class="white-sheet">
	<div class="content-slide">


		<div class="title-bar red"></div>

		<div class="wrapper slide-3-3-7">


			<div class="popups" style="position:absolute">
				<div data-effect="fade" data-duration="1000" data-target="references-overlay" data-width="600" data-height="490" class="references-button show-overlay"></div>
				<div data-effect="fade" data-duration="1000" data-target="information-overlay" data-width="600" data-height="490" class="information-button show-overlay"></div>
			</div>

			<div class="slide-title red two-line">
				Phase II study in refractory aplastic anaemia: <br />maintained response after eltrombopag discontinuation
			</div>


			<div class="content-container">

				<ul>
					<li><span>Heavily pre-treated patients, for example patients enrolled in this study, are at a high risk of infectious and bleeding complications because of pancytopenia<sup>1</sup></span>
						<ul>
							<li><span>Approximately 25% of IST-refractory patients with SAA die from bleeding or infection </span></li>
						</ul>
					</li>
					<li><span>A total of 14 patients experienced at least one serious AE during treatment<sup>2</sup></span>
						<ul>
							<li><span>The most common serious AEs reported were febrile neutropenia, sepsis and viral infection</span></li>
							<li><span>One patient experienced severe abdominal discomfort that was considered to be treatment-related by the investigators</span></li>
						</ul>
					</li>
					<li><span>None of the six deaths (14%) reported during the study were considered to be related to eltrombopag</span>
						<ul>
							<li><span>The primary cause of death was sepsis/infection due to disease (four patients)</span></li>
						</ul>
					</li>
				</ul>

			</div>

		</div>


		<div class="information-overlay overlay">

			<header>Phase II study in refractory aplastic anaemia: serious adverse events and death</header>
				
			<ul>
				<li><span>No deaths occurred during eltrombopag treatment:<sup>2</sup></span>
					<ul>
						<li><span>Two patients died of sepsis/infection within 30 days of the last dose of eltrombopag</span></li>
						<li><span>Four subjects died more than 110 days after the last dose of eltrombopag</span></li>
						<li><span>Three patients, whose primary cause of death was reported as disease under study, had fatal serious AEs of aplastic anaemia, sepsis and septic shock</span></li>
					</ul>
				</li>
			</ul>

		</div>


		<div class="references-overlay overlay">

			<header>References</header>
				
			<ul>
				<li class="navigateHref" data-navtarget="media/documents/module2/ValdezJM-2011-ClinInfectDis-v52p726.pdf"><span>Valdez JM <i>et al. Clin Infect Dis</i> 2011;52:726</span></li>
				<li class="navigateHref" data-navtarget="media/documents/module2/GlaxoSmithKline-2014-DoF-ELT112523.pdf"><span>GlaxoSmithKline. Data on File. Clinical study report #ELT112523. 2014</span></li>
			</ul>

		</div>


		

	</div>
</div>